Gabe S. Sonke

31.8k total citations · 4 hit papers
314 papers, 8.2k citations indexed

About

Gabe S. Sonke is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gabe S. Sonke has authored 314 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Oncology, 109 papers in Cancer Research and 86 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gabe S. Sonke's work include Breast Cancer Treatment Studies (95 papers), Ovarian cancer diagnosis and treatment (72 papers) and HER2/EGFR in Cancer Research (57 papers). Gabe S. Sonke is often cited by papers focused on Breast Cancer Treatment Studies (95 papers), Ovarian cancer diagnosis and treatment (72 papers) and HER2/EGFR in Cancer Research (57 papers). Gabe S. Sonke collaborates with scholars based in Netherlands, United States and Belgium. Gabe S. Sonke's co-authors include Neil K. Aaronson, Willemien J. van Driel, Jelle Wesseling, Koen Van de Vijver, Harm van Tinteren, Sabine C. Linn, Jacobien M. Kieffer, Arend G. J. Aalbers, Simone N. Koole and Erik van Werkhoven and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Gabe S. Sonke

296 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

2018 919 citations Willemien J. van Driel, Simone N. Koole et al. profile →
Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial

2015 451 citations Martijn M. Stuiver, Jacobien M. Kieffer et al. Journal of Clinical Oncology profile →
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Gabe S. Sonke et al. profile →
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

2021 161 citations Dennis J. Slamon, Patrick Neven et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Gabe S. Sonke

Since Specialization

Citations

This map shows the geographic impact of Gabe S. Sonke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabe S. Sonke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabe S. Sonke more than expected).

Fields of papers citing papers by Gabe S. Sonke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabe S. Sonke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabe S. Sonke. The network helps show where Gabe S. Sonke may publish in the future.

Co-authorship network of co-authors of Gabe S. Sonke

This figure shows the co-authorship network connecting the top 25 collaborators of Gabe S. Sonke. A scholar is included among the top collaborators of Gabe S. Sonke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabe S. Sonke. Gabe S. Sonke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial 2025 ·Nature Medicine ·Elisabeth M. Jongbloed, (unknown), Vanja de Weerd, Corine M. Beaufort, Kirsten Ruigrok-Ritstier, Mai N. Van, Jaco Kraan, Annette A. van Zweeden, (unknown), (unknown), Inge R. Konings, Gabe S. Sonke, Esther Oomen‐de Hoop, John W.M. Martens, Agnes Jager, Saskia M. Wilting	2
2	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial 2025 ·European Journal of Cancer ·(unknown), (unknown), Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), F. Van den Berkmortel, Helga Droogendijk, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), Ester Siemerink, Jolien Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
3	Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases 2025 ·The Breast ·(unknown), (unknown), Kim Monkhorst, Gabe S. Sonke, Annegien Broeks, (unknown), Daan van den Broek, Mirjam C. Boelens, Dieta Brandsma	0
4	Omission of axillary lymph node dissection in cN2-3 breast cancer patients with an excellent response on primary systemic treatment is safe: 4-year oncologic outcome of the MARI protocol 2024 ·European Journal of Cancer ·(unknown), (unknown), (unknown), Marcel P. M. Stokkel, Ewout J. N. Groen, Claudette E. Loo, Vincent van der Noort, Gabe S. Sonke, N.S. Russell, Frederieke van Duijnhoven, (unknown)	1
5	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) 2024 ·Annals of Oncology ·(unknown), Stephen B. H. Kent, Inge R. Konings, (unknown), Vincent van der Noort, E. van den Pol, (unknown), (unknown), (unknown), Frans Erdkamp, Danny Houtsma, Hendrika M. Oosterkamp, (unknown), (unknown), J. Tol, Annette A. van Zweeden, A. Elise van Leeuwen‐Stok, Gabe S. Sonke, Agnes Jager, Hedwig M. Blommestein	1
6	Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), Joost A. Agelink van Rentergem, Ivar Vermeulen, Inge R. Konings, Agnes Jager, Gabe S. Sonke, Elsken van der Wall, Sanne B. Schagen	1
7	Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels 2023 ·Scientific Reports ·Elisabeth M. Jongbloed, Maurice P.H.M. Jansen, Vanja de Weerd, (unknown), Corine M. Beaufort, Marcel Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W.M. Martens, Saskia M. Wilting, (unknown)	2
8	Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed 2023 ·Breast Cancer Research and Treatment ·Lori M. van Roozendaal, (unknown), (unknown), Luc J. A. Strobbe, Maaike de Boer, Gabe S. Sonke, Marissa C. van Maaren, Marjolein L. Smidt	1
9	Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort 2023 ·JCO Precision Oncology ·Tessa G. Steenbruggen, Denise M. Wolf, Bram Thijssen, Joyce Sanders, Sten Cornelissen, Roberto Salgado, Lorenza Mittempergher, Rajith Bhaskaran, Annegien Broeks, Esther H. Lips, Sabine Siesling, Gabe S. Sonke, Hugo M. Horlings, Laura van ‘t Veer	1
10	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant 2023 ·Breast Cancer Research ·Patrick Neven, PA Fasching, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, (unknown), Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Juan Pablo Zarate, (unknown), A. Chakravartty, (unknown), Dennis J. Slamon	33
11	A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials 2023 ·Journal of Clinical Epidemiology ·Laurien M. Buffart, (unknown), Martijn M. Stuiver, Neil K. Aaronson, Gabe S. Sonke, Johannes Berkhof, Peter M. van de Ven	1
12	Peroperative extent of peritoneal metastases affects the surgical outcome and survival in advanced ovarian cancer 2022 ·Gynecologic Oncology ·(unknown), Maurits P. Engbersen, (unknown), Marta López‐Yurda, Max J. Lahaye, Geerard L. Beets, Christianne Lok, Gabe S. Sonke, Willemien J. van Driel	4
13	Characteristics of long-term survival in advanced stage ovarian cancer: a nationwide cohort in the Netherlands 2022 ·European Journal of Gynaecological Oncology ·(unknown), Gabe S. Sonke, (unknown), Hugo M. Horlings, (unknown), (unknown)	0
14	Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance 2022 ·npj Breast Cancer ·Marlous Hoogstraat, Esther H. Lips, Isabel Mayayo‐Peralta, Lennart Mulder, Petra Kristel, Ingrid van der Heijden, Stefano Annunziato, Maartje van Seijen, Petra M. Nederlof, Gabe S. Sonke, Wilbert Zwart, Jelle Wesseling, Lodewyk F.A. Wessels	23
15	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits 2022 ·JNCI Journal of the National Cancer Institute ·(unknown), Thea M. Mooij, Anouk Pijpe, Gabe S. Sonke, Marian J.E. Mourits, Nadine Andrieu, Antonis C. Antoniou, Douglas F. Easton, Christoph Engel, David E. Goldgar, Esther M. John, Karin Kast, Roger L. Milne, Håkan Olsson, Kelly‐Anne Phillips, Mary Beth Terry, John L. Hopper, Flora E. van Leeuwen, Matti A. Rookus	7
16	Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer 2018 ·Obstetrical & Gynecological Survey ·Willemien J. van Driel, Simone N. Koole, Karolina Sikorska, Jules H. Schagen van Leeuwen, Henk W.R. Schreuder, Ralph H.M. Hermans, Ignace H. J. T. de Hingh, Jacobus van der Velden, Henriëtte J.G. Arts, Leon F.A.G. Massuger, Arend G. J. Aalbers, Victor J. Verwaal, Jacobien M. Kieffer, Koen Van de Vijver, Harm van Tinteren, Neil K. Aaronson, Gabe S. Sonke	30
17	Enrichment of high-grade tumors in breast cancer gene expression studies 2017 ·Breast Cancer Research and Treatment ·Maartje van Seijen, Antien L. Mooyaart, Lennart Mulder, Marlous Hoogstraat, Caroline A. Drukker, Claudette E. Loo, (unknown), Gabe S. Sonke, Jelle Wesseling, Esther H. Lips	4
18	Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population 2017 ·European Journal of Cancer ·Marissa C. van Maaren, (unknown), Paul D.P. Pharoah, Annemieke Witteveen, Gabe S. Sonke, Luc J. A. Strobbe, Philip Poortmans, Sabine Siesling	30
19	BRCA1 -Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency 2016 ·Clinical Cancer Research ·Esther H. Lips, (unknown), (unknown), Lennart Mulder, Gabe S. Sonke, Lizet E. van der Kolk, Jelle Wesseling, Frans B.L. Hogervorst, Petra M. Nederlof	15
20	Diagnostic research in benign prostatic hyperplasia - from sensitivity to neural networks 1999 ·Current Opinion in Urology ·Gabe S. Sonke, Lambertus A. Kiemeney	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact